Exploring Future Prospects of Medical AI in Cancer Treatment: JPI Seminar

JPI Seminar: Future of Medical AI in Oncology

On May 22, 2026, from 9:30 AM to 11:30 AM, the Japan Planning Institute (JPI) will host a vital seminar focusing on the clinical application and social implementation of medical AI in cancer treatment. This event invites Takashi Hamamoto, a respected leader from the National Cancer Center's Medical AI Research and Development department, to explore how AI is revolutionizing cancer healthcare.

Seminar Details

As advancements in deep learning and machine learning accelerate, supported by robust information technology and data infrastructure, AI technologies, including generative AI, have begun to transform not only society but also the medical field significantly. However, translating research outcomes in medical AI into clinical applications requires adherence to relevant laws and ethical guidelines, as well as research designs that prioritize clinical needs. Strong collaboration between clinical and research settings is vital for success.

In his presentation, Hamamoto will highlight the progress made in significant AI projects over the last decade, emphasizing the current challenges and future directions in the domain of cancer treatment. The seminar aims to provide insights into medical AI research and development, allowing participants to grasp the potential impacts this technology may have.

Topics of Discussion

1. Trends in Medical AI Research and Development

- Domestic Trends: An overview of the developments in Japan regarding medical AI, addressing unique challenges and innovations localized to the country.
- Global Trends: Exploring how other countries are embracing and integrating medical AI into healthcare practices.

2. Medical AI Applications in Clinical Settings

- Endoscopic Diagnosis Support AI Project: Aimed at enhancing diagnostic accuracy during endoscopic procedures.
- AI Development Support Platforms: Tools and frameworks to assist researchers in AI development initiatives.
- Dermatology AI Project: Focused on advancements in diagnosing skin tumors through AI technology.
- Fetal Heart Ultrasound Screening System: Exploring the use of AI in improving prenatal screening processes.
- Assessing Atrial Fibrillation Conditions: Analyzing how AI can contribute to better understanding and diagnosing heart conditions.

3. Opportunities and Challenges with Generative AI

Participants will engage in a rich dialogue around the evolving capabilities of generative AI, discussing its potential and challenges in a medical context.

4. Q&A Session

An opportunity for attendees to interact directly with Hamamoto and pose questions about the integration of AI in cancer care and medical research.

5. Networking Event

This seminar offers a unique chance for networking with industry peers and engaging in discussions that could lead to practical, impactful collaborations.

Participation Options

- In-Person Attendance: Limited to available seating; archive playback is not included.
- Live Streaming: Attend remotely; archival access is also not included.
- Archive Access: Available for those who cannot attend live events.

For in-person or live-streaming participants, an optional archive playback can be added for a special fee of 18,500 yen (tax included).

Registration Fees

- Individual: 37,970 yen (tax included)
- Group (2 or more from the same organization): 32,970 yen per person (tax included)
- Special Rate for Local Government Officials: 11,000 yen per person (limited to in-person or live streaming and applicable only to the same attendee type).

For further details on how to register and participate in this groundbreaking seminar, please visit JPI Seminar Registration.

Network and Collaborate

Post-seminar, participants can connect with the speaker, Hamamoto, and fellow attendees to foster professional relationships, exchange ideas, and explore new business opportunities within the healthcare sector. Questions for the speaker can be submitted, and additional support is available for building valuable networks.